Latin American consensus on the medical oncologic management of early-stage HR+/HER2- breast cancer: Addressing regional disparities in Spanish-speaking countries.

With longer follow-up presented at the ESMO Congress 2025, ribociclib continued to show a significant iDFS advantage over endocrine therapy alone (hazard ratio [HR] 0.72, 95% CI 0.62-0.83), with an absolute 5-year iDFS improvement of 4.5% and evidence of a carryover effect beyond the 3-year treatment course [ 112 ]; a positive trend toward improved overall survival (OS) was also observed (HR 0.80, 95% CI 0.64-1.00) [ 112 ].

also in 11,005 other papers